News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

R&D
3rd World ADC Asia feature
Partner Content

3rd World ADC Asia

Optimising Physiochemical, Potency & Impurity Analytical Methods to Ensure Regulatory Compliance

R&D
3rd ADC Analytical Development Summit feature
Partner Content

3rd ADC Analytical Development Summit

The 3rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure y

R&D
14th World ADC London 2024 event
Partner Content

14th World ADC London 2024

We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collabor

Debates & Insights

News

News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content